SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 10/15/19

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2)	Approved 10/19	
		VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2)	Phase III	
		Infrainguinal revascularized PAD (2)	Phase III	
		Pediatric VTE (2)	Phase III	
	INVOKANA® (canagliflozin)	Treatment of Diabetic Nephropathy in adults with T2DM (2)	Approved 9/19	Filed 7/19
	aprocitentan	Difficult to treat hypertension (2)	Phase III	Phase III
Immunology	TREMFYA® (guselkumab)	Psoriatic arthritis	Filed 9/19	Phase III
		Crohn's Disease	Phase IIB/III	Phase IIB/III
		Pediatric Psoriasis	Phase III	Phase III
	SIMPONI®	Pediatric Ulcerative Colitis	Phase III	Phase III
	STELARA® (ustekinumab)	Pediatric Psoriasis (6-11 year olds)	Filed 9/19	Filed 6/19
		Ulcerative Colitis	Filed 12/18	Approved 9/19
		Lupus	Phase III	Phase III
Infectious Diseases and Vaccines	Rilpivirine Long Acting nanosuspension for injection	HIV Infection	Filed 4/19	Filed 7/19
	pimodivir (JNJ-3872)	Influenza A (2)	Phase III	Phase III
	VAC52150	Monovalent Ebola Virus Vaccine	Phase III	Phase III
Neuroscience	SPRAVATO™ (esketamine)	Treatment-resistant depression	Approved 3/19	Filed 10/18
		Major depressive disorder who have active suicidal ideation with intent	Filed 10/19	Phase III
	ponesimod	Monotherapy for multiple sclerosis	Phase III	Phase III
	paliperidone palmitate 6 month long-acting injectable	Treatment of Schizophrenia	Phase III	Phase III
Oncology	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezimib, thalidomide and dexamethasone (MMY 3006, CASSIOPEIA) (2)	Approved 9/19	Filed 3/19
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY3008, MAIA) (2)	Approved 6/19	Filed 3/19
		Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III
		Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2)	Phase III	
		Amyloidosis (AMY 3001) (2)	Phase III	Phase III
		Subcutaneous Formulation in patients with relapsed or refractory multiple myeloma (MMY3012, COLUMBA) (2)	Filed 7/19	Filed 7/19
		Smoldering multiple myeloma (SMM3001) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3019, CEPHEUS) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3014, PERSEUS) (2)	Phase III	Phase III
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolant Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Previously untreated and relapsed/refractory patients with Waldenstrom's Macroglobulinemia in combination with Rituximab (PCYC-1127) (2)	Approved 8/18	Approved 8/19
		Frontline Chronic Lymphocytic Leukemia in combination with Rituximab (Young and Fit) (ECOG 1912) (2)	Phase III	Phase III
		Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Approved 1/19	Approved 8/19
		Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (2)	Phase III	Phase III
		Frontline Chronic graft-versus-host-disease (cGVHD) (2)	Phase III	Phase III
		Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III	Phase III
	ERLEADA® (apalutamide)	Metastatic castrate sensitive prostate cancer (TITAN)	Approved 9/19	Filed 06/19
		Localized prostate cancer	Phase III	Phase III
		High risk prostate cancer (PROTEUS)	Phase III	Phase III
	apalutamide/ abiraterone acetate	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III
	BALVERSA™ (erdafitinib)	Urothelial cancer (2)	Approved 4/19	Phase III
	niraparib (PARP inhibitor)	L3 Prostate cancer metastatic castration-resistant	Phase IIB	Phase IIB
	niraparib / abiraterone acetate	L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone	Phase III	Phase III
	BCMA CAR-T	Relapsed refractory multiple myeloma (2)	Phase II	Phase II
Pulmonary Hypertension	OPSUMIT®	Fontan-palliated in adolescent (>12 years old) and adult patients	Phase III	Phase III
		Pediatric pulmonary arterial hypertension	Phase III	Phase III
		Chronic thromboembolic pulmonary hypertension	Complete Response 1/19	Filed 8/18
	UPTRAVI®	Pulmonary arterial hypertension IV	Phase III	Phase III
		Chronic thromboembolic pulmonary hypertension	Phase III	Phase III

*** This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.**

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViiV Healthcare Ltd; aprocitentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech;

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
Selective Highlights as of October 15, 2019

NMEs APPROVED 2019	NMEs IN REGISTRATION	NME PLANNED FILINGS 2019-2023*	
Oncology	**Neuroscience**	**Oncology**	**Neuroscience**
ERLEADA® (apalutamide) (EU) Non-metastatic prostate cancer	**SPRAVATO™ (Esketamine) (EU)** Treatment resistant depression	**Niraparib** Metastatic castration-resistant prostate cancer (mCRPC)	**Ponesimod** Monotherapy for multiple sclerosis
BALVERSA™ (erdafitinib) (US) Urothelial cancer		**BCMA CAR-T** Multiple Myeloma	**Seltorexant** Adjunctive treatment for major depressive disorder
Neuroscience		**BALVERSA™ (erdafitinib) (EU)** Urothelial cancer	**Infectious Diseases & Vaccines**
SPRAVATO™ (Esketamine) (US) Treatment resistant depression		**Lazertinib** Non Small Cell Lung Cancer	**Pimodivir** Influenza A
		Cusatuzumab Acute myeloid leukemia	**RSV Sr vaccine** RSV vaccine
		JNJ-6372 (EGFR/cMET) Solid Tumor	**Cardiovascular & Metabolism**
		JNJ-7957 (BCMA/CD3), JNJ-7564 (GPRC5D/CD3) Multiple myeloma	**CNGB3 and CNGA3 AAV Gene Therapy** Achromatopsia
		Immunology	**RPGR AAV Gene Therapy** X-linked retinitis pigmentosa
		JNJ-4500 Anti-NKG2D Crohn's disease	**Aprocitentan** Difficult to treat hypertension

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; BCMA CAR-T licensed from Legend Biotech; Cusatuzumab licensed from Argenx; Lazertinib licensed from Yuhan Corporation; JNJ-4500 Anti-NKG2D licensed from Novo Nordisk; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; Seltorexant being developed in collaboration with Minerva Neurosciences; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (JNJ-6372, JNJ-7957, JNJ-7564)

Johnson & Johnson